Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Food or edible as carrier for pharmaceutical
Reexamination Certificate
2007-06-19
2007-06-19
Tran, S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Food or edible as carrier for pharmaceutical
C426S072000, C426S073000
Reexamination Certificate
active
11526383
ABSTRACT:
Provided by the present invention are novel and non-obvious nutrient supplements that preferably comprise minerals, vitamins, amino acids, and agents capable of delivering cysteine in vivo. The nutrient supplements desirably are capable of promoting metallothioneins, and optionally, promoting the removal of excess metals from the bloodstream. Also provided by the invention are methods of treating autism involving administration of the nutrient supplements. The methods include treatment to prevent or slow down the onset of autism once a predisposition for the development of autism has been detected, and treatment to alleviate or reverse the symptoms of autism once autism has been diagnosed. The invention further provides methods of administering the nutrient supplements in the treatment of other diseases, disorders and conditions, that would benefit from such administration, especially those that would benefit from metallothionein promotion and/or removal of excess metals from the bloodstream.
REFERENCES:
patent: 5556644 (1996-09-01), Chandra
patent: 5976579 (1999-11-01), McLean
patent: 6132724 (2000-10-01), Blum
patent: 6143332 (2000-11-01), McLean
patent: 6245360 (2001-06-01), Markowitz
patent: 6399114 (2002-06-01), Foreman
patent: 2001/0055645 (2001-12-01), Flook et al.
patent: 0 891 719 (1999-01-01), None
patent: WO 91/11117 (1991-08-01), None
patent: WO 9111117 (1991-08-01), None
patent: WO 98/41113 (1998-09-01), None
patent: WO 00/67596 (2000-11-01), None
patent: WO 01/26642 (2001-04-01), None
Walsh et al., “Eleveated Blood Cooper/Zinc Ratios in Assaultive Young Males,” Physiology & Behavior, vol. 62, No. 2, 1997.
Isaacson et al., “Autism: A Retrospectice Outcome Study of Nutrient Therapy,” Journal of Applied Nutrition, vol. 48, No. 4, 1996.
Kirkman Laboratories, Inc., Kirkman's HypoAllergenic NuThera® Capsules [http://www.kirkmanlabs.com/products/articles
utherap5p.htm] 1-3 (Mar. 2002).
Kirkman Laboratories, Inc., “Super NuThera®” [http://www.kirkmanlabs.com/products/articles/supernuthera.htm] 1-19 (Mar. 11, 2002).
Kirkman Laboratories, Inc., “Super Nu-Thera with P5P” [http://www.kirkmanlabs.com/products/articles/supernutherap5p.htm] 1-3 (Mar. 11, 2002).
Maret, “The Function of Zinc Metallothionein: A Link between Cellular Zinc and Redox State”, J.Nutr. 130(No. 5, Suppl.): 1455S-1458S (May 2000).
Sullivan et al., “Metallothionein Expression Is Increased in Monocytes and Erythrocytes of Young Men during Zinc Supplementation”, J.Nutr. 128:7077-713 (1998).
Suzuki et al, “Table I. Factors that induce thionein synthesis in cultured cells in vivo”,In, Metallothionein III: Biological Roles&Medical Implications, Birkhauser Verlag, un-numbered page (1993).
Walsh et al., “Disordered Metal Metabolism in a Large Autism Population”, Abstract NR823, American Psychiatric Association Annual Meeting, New Orleans, LA (May 10, 2001).
Walsh et al. “Elevated Blood Copper/Zinc Ratios in Assaultive Young Males”Physiology&Behavior, 62(2):327-329 (1997).
Walsh et al., “Metallothionein and Autism”, Pfeiffer Treatment Center, 1804 Centre Point Drive, Naperville, Illinois, 60563 (Oct. 2001).
Walsh et al. “Metallothionein Protein Dysfunction in Autism spectrum Disorders”, Abstract forInternational MeetingForAutism Research, San Diego, CA (Nov. 9-10, 2002).
Autism Research Publication, “Parent Ratings of Behavioral Effects of Drugs,. Nutrients, and Diets.”ART Publ. 34, Autism Research Institute, 4182 Adarns Avenue, San Diego, CA 921 16 (Sep. 2000).
Fischer et al., “Commentary: Recent excitement regarding metallothionein”,Proc. Natl Acad. Sci. USA. 95:3333-3334 (Mar. 1998).
Isaacson et al., “Autism: A Retrospective Outcome Study of Nutrient Therapy,”Journal of Applied Nutrition, 48(4):2-6 (1996).
Jacob et al., “Control of zinc transfer between thionein, metallothionein, and zinc proteins,”Proc. Natl Acad. Sci. USA, 95:3489-3494 (Mar. 1998).
Jiang et al., “The Glutathione redox couple modulates zinc transfer from metallothionein to zinc-depleted sorbitol dehydrogenate,”Proc. Natl Acad. Sci. USA. 95 :3483-3488 (Mar. 1998).
Karen, from the autismandenzymes Yahoo.Group, William Walsh -PfeifferJMetallathionein* [http: //www.bbbautism.dan˜william—walsh.html] 1-9.
Kirkman Laboratories, Inc., “Kirkman's Amino-Support” 1 [http: //www .kirkmanlabs.com/products/articles/aminosupport.htm] 1-5 (Mar. 11, 2002).
Cutler, “Pyridoxine and Trace Element Therapy in Selected Clinical Cases.” OrthomolecularPsychiatry. vol. 3. No. 2, pp. 89-95 (1 974).
Isaacson et al., “A Retrospective Outcome Study of Nutrient Therapy.” Journalof AppliedNutrition, vol. 48. No. 4, pp. 11 0-1 18 (1 996).
Adams et al., “Vitamin, mineral supplements benefits people with autism”.
Usman Anjum Iona
Walsh William John
Merchant & Gould
The Health Research Institute
Tran S.
LandOfFree
Nutrient supplements and methods for treating autism and for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nutrient supplements and methods for treating autism and for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nutrient supplements and methods for treating autism and for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3808473